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Abstract
Background: Traumatic brain injury (TBI) initiates interrelated inflammatory and coagulation cascades characterized by
wide-spread cellular activation, induction of leukocyte and endothelial cell adhesion molecules and release of soluble
pro/antiinflammatory cytokines and thrombotic mediators. Resuscitative care is focused on optimizing cerebral
perfusion and reducing secondary injury processes. Hypertonic saline is an effective osmotherapeutic agent for the
treatment of intracranial hypertension and has immunomodulatory properties that may confer neuroprotection. This
study examined the impact of hypertonic fluids on inflammatory/coagulation cascades in isolated head injury.
Methods: Using a prospective, randomized controlled trial we investigated the impact of prehospital resuscitation
of severe TBI (GCS < 8) patients using 7.5% hypertonic saline in combination with 6% dextran-70 (HSD) vs 0.9%
normal saline (NS), on selected cellular and soluble inflammatory/coagulation markers. Serial blood samples were
drawn from 65 patients (30 HSD, 35 NS) at the time of hospital admission and at 12, 24, and 48-h post-
resuscitation. Flow cytometry was used to analyze leukocyte cell-surface adhesion (CD62L, CD11b) and
degranulation (CD63, CD66b) molecules. Circulating concentrations of soluble (s)L- and sE-selectins (sL-, sE-
selectins), vascular and intercellular adhesion molecules (sVCAM-1, sICAM-1), pro/antiinflammatory cytokines [tumor
necrosis factor (TNF)-a and interleukin (IL-10)], tissue factor (sTF), thrombomodulin (sTM) and D-dimers (D-D) were
assessed by enzyme immunoassay. Twenty-five healthy subjects were studied as a control group.
Results: TBI provoked marked alterations in a majority of the inflammatory/coagulation markers assessed in all
patients. Relative to control, NS patients showed up to a 2-fold higher surface expression of CD62L, CD11b and
CD66b on polymorphonuclear neutrophils (PMNs) and monocytes that persisted for 48-h. HSD blunted the
expression of these cell-surface activation/adhesion molecules at all time-points to levels approaching control
values. Admission concentrations of endothelial-derived sVCAM-1 and sE-selectin were generally reduced in HSD
patients. Circulating sL-selectin levels were significantly elevated at 12 and 48, but not 24 h post-resuscitation with
HSD. TNF-a and IL-10 levels were elevated above control throughout the study period in all patients, but were
reduced in HSD patients. Plasma sTF and D-D levels were also significantly lower in HSD patients, whereas sTM
levels remained at control levels.
Conclusions: These findings support an important modulatory role of HSD resuscitation in attenuating the
upregulation of leukocyte/endothelial cell proinflammatory/prothrombotic mediators, which may help ameliorate
secondary brain injury after TBI.
Trial registration: NCT00878631.
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Traumatic brain injury (TBI) remains a leading cause of
death and persistent neurocognitive impairment in civi-
lian and military casualties [1]. The extent of brain
damage is determined by the severity of primary mechan-
ical injury and intensity of secondary biomolecular injury
cascades causing neuroinflammation that contributes to
cerebral edema, raised intracranial pressure and delayed
cellular destruction [2]. TBI patients are also vulnerable
to ensuing pathophysiological insults including hypoten-
sion and hypoxemia [3], initiating global ischemia/reper-
fusion and systemic immunoinflammatory responses that
worsen neurological outcome and often lead to develop-
ment of multiorgan dysfunction [4,5].
Prehospital care is a major determinant of long-term
outcome in TBI patients. Current management involves
expeditious infusion of crystalloids and colloids to limit
secondary insults by hemodynamic stabilization and
optimization of cerebral perfusion [6]. Yet, the ideal
fluid for initial resuscitation of TBI remains unclear [7];
due to in part to a lack of adequately powered clinical
trials comparing osmotic agents in neurotrauma [8].
Overzealous crystalloid resuscitation often serves to
exacerbate delayed posttraumatic complications, includ-
ing inflammatory-mediated cellular injury via enhanced
cytokine release, endothelial activation, adhesion mole-
cule expression and coagulopathy [9]. Conversely, resus-
citation with hypertonic saline, alone or combined with
dextran (HS/D), is emerging as effective first-line
osmotherapeutic alternative for treatment of intracranial
hypertension and cerebral edema [10,11]. Beyond its
osmotic and hemodynamic properties, compelling
laboratory and clinical data indicate that HS/D exerts
immunomodulatory and antiinflammatory effects
[12-15], including blunted cellular activation, cytokine
production and adhesion molecule expression, that may
also convey neuroprotection against brain secondary
injury cascades [16,17].
It is increasingly evident that TBI elicits interdependent
CNS and systemic inflammatory and coagulation cas-
cades that contribute to secondary neuropathological
sequelae [4,18]. These innate host defence responses to
cerebral insults are characterized by rapid activation of
resident microglia and astrocytes [19], brain microvascu-
lar ECs [20] and peripheral blood leukocytes (PMNs,
monocytes) [21,22], with increased expression of multiple
surface-active and soluble mediators, including inflam-
matory cytokines [23], adhesion molecules [24,25] and
coagulation cofactors [18,26]. TNF-a is a central media-
tor of neuroinflammation after brain injury [19], inducing
generalized endothelial activation/injury [27], direct neu-
rotoxicity [28], reduced BBB integrity [23,29], and
upregulated adhesion molecule expression [24,25,30],
thus promoting leukocyte-EC interactions and cellular
infiltration of injured brain parenchyma [31,32].
Based on the multi-step paradigm of leukocyte traf-
ficking, inflammatory cells are recruited into the micro-
vasculature via sequential adhesive interactions of
selectins and integrins with their respective immunoglo-
bulin family ligands [29]. Initial tethering and rolling of
marginated cells along the vessel wall is mediated by L-
(leukocyte; CD62L) and E- (endothelial; CD62E) selec-
tins binding to sialyl-Lewis
X carbohydrate counter-
receptors. Subsequent b2-integrin (CD11b)-dependent
firm adhesion to endothelial ligands for intercellular and
vascular cell adhesion molecules (ICAM-1, CD54;
VCAM-1, CD106) allows leukocyte transmigration into
damaged tissues [31]. Simultaneously, ligand-binding
triggers leukocyte effector functions, such as respiratory
burst and degranulation of azurophilic (CD63) and spe-
cific (CD66b) proteins [33]. Sequestration of activated
leukocytes within the CNS inflicts secondary injury
through generation of neurototoxic reactive species,
granular proteases, and inflammatory cytokines, ulti-
mately producing endothelial destruction, thrombosis
and end-organ failure [34,35].
The vascular endothelium provides a critical interface
for host inflammatory and coagulation responses to
injury. Cytokine-activated or damaged ECs participate in
hemostatic balance via synthesis of procoagulant TF and
anticoagulant TM endothelial glycoproteins [36]. TBI
patients are prone to coagulation abnormalities since the
brain is rich in TF [26], which initiates the extrinsic path-
way causing local and systemic hemostatic disturbances
[37]. TNF-a is also a potent inducer of TF by ECs and
monocytes [38,39], but inhibits cell-surface expression of
TM [40], thus shifting the hemostatic balance towards
intravascular thrombosis and hyperfibrinolysis with
release of D-D fibrin degradation products [41]. Soluble
isoforms of adhesion and coagulation molecules are also
liberated during inflammation serving as circulating mar-
kers of endothelial activation or injury [42]. Collectively,
these changes exemplify the molecular crosstalk between
coagulation-inflammatory pathways as a key aspect in
secondary brain injury progression [26,43].
In light of our previous findings in the same cohort of
TBI patients [44] showing dramatically elevated S100B,
NSE, and MBP brain-injury biomarkers in serum from
patients resuscitated with NS relative to HSD-treated
patients, along with the knowledge that these specific
cellular injury markers are associated with disruption of
the BBB and neuroinflammation [45,46], we hypothe-
sized that prehospital resuscitation of head injury
patients using 7.5% hypertonic saline with 6% dextran-
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cellular and soluble inflammatory/coagulation markers
related to secondary brain injury cascades.
Materials and methods
Patients and Controls
Using as an ap r i o r isubgroup analysis within our pre-
viously reported, larger prospective randomized con-
trolled trial to evaluate hypertonic fluid resuscitation
[47], biomarkers of leukocyte and EC activation, inflam-
mation and coagulation were studied in sixty-five severe
TBI patients (Table 1). Patients were eligible for the
study if at any time during prehospital care they experi-
enced loss of consciousness due to isolated blunt head
trauma and/or had a Glasgow Coma Scale (GCS) score
of 8 or less. Patients were excluded if they had primary
penetrating injury, had suffered severe life-threatening
injury to organs other than the brain, received previous
intravenous fluid therapy ≥ 50 mL, a time interval
between arrival at scene and vascular access which
exceeded 4 hours, were younger than 16 years, were
pregnant, or had vital signs absent prior to randomiza-
tion. The Phase II study was approved by the Research
Ethics Boards of all participating agencies, along with
the Canadian Therapeutic Products Directorate and
registered at ClinicalTrials.gov (Identifier:
NCT00878631). Prehospital informed consent was
waived in accordance with the Tri-Council Policy
Agreement for Research in Emergency Health Situations
(Article 2.8). Patients were enrolled by advance life sup-
port or critical care paramedics, and informed consent
was subsequently waived for blood sampling for this
substudy. An age-matched (38.8 ± 8.5 yrs) control
group of 25 asymptomatic adult donors, with no history
of brain injury, were analyzed for determination of the
selected cellular and soluble biomarkers after obtaining
informed consent. Studies on human subjects were car-
ried out according to the principles of the Declaration
of Helsinki.
Study Design and Procedures
Eligible adult patients were randomly assigned to receive
either a single prehospital bolus infusion of 250-mL of
7.5% hypertonic saline admixed with 6% dextran-70
(HSD; RescueFlow® BioPhausia AB, Stockholm Sweden)
as the experimental treatment, or 250-mL of the stan-
dard 0.9% normal saline (NS). Paramedics administered
the treatment solutions as the initial resuscitation fluid
given within 4 hours of the incident. After administra-
tion of the study fluid, all subsequent clinical treatment
was performed according to best practice guidelines
established by the American College of Surgeons
Advanced Trauma Life Support (ATLS; http://www.facs.
org/trauma/atls/edguidelines.html) and the Brain
Table 1 Patient demographics and clinical characteristics
on admission according to prehospital fluid resuscitation
treatment groups.
Variables Resuscitation Group P Value
†
HSD NS
Demographics
No. of Patients,
n
30 35
Age, yrs 41.8 ± 17.4 42.8 ± 18.8 0.85
a
Sex Ratio
(M/F)
19/11 25/10 0.79
c
Vital signs
GCS on
Admission
5.6 ± 2.8 5.9 ± 2.6 0.53
b
SBP, mm Hg 133.3 ± 16.2 130.8 ± 28.3 0.83
a
ISS 34.9 ± 9.5 31.7 ± 14.6 0.19
b
APACHE II 12.5 ± 5.9 14.8 ± 5.1 0.24
b
SOFA 4.9 ± 1.7 4.9 ± 2.5 0.72
b
MODS 3.8 ± 1.5 5.0 ± 3.3 0.64
b
Laboratory
Values
Hb, g/dL 11.3 ± 1.6 11.9 ± 2.1 0.39
a
Hct, % 32.9 ± 5.0 34.7 ± 5.9 0.40
a
Plt, 10
9/L 206.2 ± 41.5 219.5 ± 56.4 0.40
a
pH 7.34 ± 0.06 7.33 ± 0.05 0.69
b
BE, mEq/L -2.1 ± 3.2 -2.4 ± 3.7 0.76
a
aPTT, s 26.2 ± 5.3 24.4 ± 6.1 0.63
a
INR 1.08 ± 0.21 1.12 ± 0.23 0.25
b
Na, mmol/L 146.9 ± 4.5 143.5 ± 5.2 0.03
a
Cl, mmol/L 115.4 ± 5.0 111.9 ± 7.0 0.07
a
Osmolality,
mOsm/kg
316.0 ± 20.1 306.7 ± 29.1 0.05
a
Fluids
Total fluids
prehospital, L
0.4 ± 0.3 0.3 ± 0.1 0.83
a
Total fluids in-
hospital, L
5.4 ± 2.2 5.3 ± 2.5 0.96
a
Outcomes
GOS 3.7 ± 1.3 3.5 ± 1.5 0.81
b
Length of stay,
d
14.1 ± 13.6 14.7 ± 12.5 0.90
a
Mechanical
Ventilation, d
6.6 ± 5.2 9.1 ± 5.8 0.71
a
Mortality,
n (%)
4 (13.3) 6 (17.1) 0.67
c
Abbreviations (normal ranges): NS, normal saline; HSD, hypertonic saline plus
dextran; GCS, Glasgow Coma Scale; ISS, Injury Severity Score; APACHE II, Acute
Physiologic and Chronic Health Evaluation; SOFA, Sequential Organ Failure
Assessment; MODS, Multiple Organ Dysfunction Score; Hb, hemoglobin (12-
18); Hct, hematocrit (37-52); Plt, platelets (130-400); aPTT, activated partial
thromboplastin time (25-35 s); INR, International Normalized Ratio (0.8-1.2); BE,
base excess (-2/+2); pH (7.35-7.45); GOS, Glasgow Outcome Scale score.
Unless otherwise stated, results are expressed as mean ± standard deviation
(SD);
†statistical significance of differences between resuscitation treatment
groups were assessed with
at-test,
bMann-Whitney U-test, or
cChi-square test
as appropriate, with significance set at P <. 0 5 .
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site/PageServer?pagename=Guidelines). This included
ongoing resuscitation by prehospital personnel with
additional crystalloid as per existing protocols. At no
point during initial or subsequent treatment was the
standard-of-care withheld. Clinical data collected upon
hospital admission included age, gender, mechanism of
injury, and Injury Severity Score (ISS). Acute neurologic
status was assessed by paramedics at the accident scene
prior to resuscitation based on the patient’s level of con-
sciousness as categorized by GCS score. Motor response,
verbal response and response to pain were noted, pro-
ducing a total score from 3-15; with a range of 3-8 indi-
cating severe injury. Severity of illness and organ
dysfunctions was quantified and defined by Acute Phy-
siologic and Chronic Health Evaluation (APACHE II),
Sequential Organ Failure Assessment (SOFA) and Mul-
tiple Organ Dysfunction Score (MODS) at the time of
admission to the ICU. In addition, neurological outcome
at the time of hospital discharge (or ≤ 30 days) was
assessed in consenting patients using the Glasgow Out-
come Scale (GOS). The GOS is the most widely used
method to describe overall outcome after head injury
and is based upon the ability of recovering TBI patients
to perform activities of daily living and the degree of
assistance required. GOS was graded as follows: 1, indi-
cates death; 2, persistent vegetative state; 3, severely dis-
abled; 4, moderately disabled; 5, good recovery. GOS
scores were further dichotomized into Good (GOS 4-5)
or Poor (GOS 1-3) outcome, as previously described
[44].
Blood Sample Collection
Serial venous blood samples (totaling 25 mL) were
drawn from each patient as soon as possible after
admission to the emergency department and again at
12-, 24- and 48-h post-resuscitation. Specimens for cel-
lular and soluble biomarker analyses were obtained from
patients and controls using an evacuated tube collection
system containing the appropriate anticoagulants or
nonadditive tubes (Vacutainer, Becton Dickinson,
Rutherford, NJ).
Routine Clinical Hematology and Coagulation Analyses
Whole blood samples collected into trisodium citrate
and K2EDTA tubes (Becton-Dickinson) at admission
were analyzed for hematogical and hemostatic para-
meters using standard clinical chemistry techniques.
Complete blood counts including hemoglobin (Hb),
hematocrit (Hct), differential leukocyte and platelet
(Plt) counts were performed using an automated
Hematology Analyzer (Coulter A
CTd i f f2 ,B e c k m a n -
Coulter, Hialeah, FL). Prothrombin time (PT, s) and
activated partial thromboplastin time (aPTT, s) were
measured by a Blood Coagulation System; Interna-
tional Normalized Ratio (INR) was calculated and
reported by the same instrument and was used as a
surrogate for PT to account for institutional variability
in this marker.
Analyses of Plasma sTF, sTM, and D-D Concentrations
Trisodium citrate, sodium heparin, and K2EDTA antic-
oagulated blood samples were double centrifuged at
3000 ×g for 15 min to obtain platelet-poor plasma,
which was stored in aliquots frozen at -80°C until analy-
sis at a later date. Plasma concentrations of sTF, sTM
and D-D were analyzed using commercially available
IMUBIND quantitative ELISA kits according to the
manufacturer’s instructions (American Diagnostica Inc,
Stamford, CI). Briefly, plasma samples for determination
of sTF, sTM and D-D, respectively, were diluted 1:4, 1:5
and 1:50 with assay diluent; standards, samples, controls,
and conjugate were incubated in precoated 96-well
microplates. Any TF, TM and D-D present was sand-
wiched by the immobilized capture antibody and the
enzyme-linked monoclonal antibody specific for these
analytes. Following a wash to remove any unbound sub-
stances and/or antibody enzyme reagent, substrate solu-
tion was added to the wells allowing the colorometic
reaction in proportion to the amount of sTF, sTM and
D-D bound. The color development was stopped and
the absorbance read at 450 nm with wavelength correc-
tion in an automated microplate photometer (EL340,
BIO-TEK Instruments, Winooski, VT); protein concen-
trations in each sample were calculated according to the
standard curve of mean optical densities of duplicate
incubations. The lowest analytical detection limits for
T F ,T M ,a n dD Da r e1 0p g / m L ,0 . 3n g / m La n d2n g /
mL, respectively.
Assessment of Cell-Surface Adhesion and Degranulation
Molecules
Simultaneous multi-colour direct staining and flow cyto-
metric analysis of granuloctye and monocyte cell mem-
brane adhesion and degranulation molecules were
performed using 100-μL aliquots of fresh untreated
whole blood. Samples were pipetted directly into 12 ×
75 mm polystyrene Falcon tubes and incubated with
saturating concentrations of anti-CD14-APC, anti-
CD62L-FITC, anti-CD11b-PE, anti-CD66b-FITC, and
anti-CD63-PE surface stains (BD Biosciences, San José,
CA) for 20 min at room temperature in the dark.
Appropriate isotype-matched mAbs were added simulta-
neously to separate tubes as indicators of autofluores-
cence and non-specific antibody binding. Red blood
cells were lysed by addition of 2 mL of 1 × FACS™ Lys-
ing Solution for 10 min, and centrifuged at 500 ×g 5
min at 20°C. The supernatant was washed with Cell-
WASH™ and cell pellets resuspended in 400μ of 1% par-
aformaldehyde. Stained cell suspensions were acquired
on a dual-laser FACSCalibur flow cytometer equipped
with a 15-mW 488-nm air-cooled argon-ion laser
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ciences). Instrument optical alignment, fluidics and day-
to-day variability were monitored and adjusted using
CaliBRITE® fluorescence beads and FACSComp® soft-
ware. For each sample, 103 events were collected as list
mode data at a flow rate of 500 events/sec using Cell-
Quest® software, with a live gate set using a bivariate
dotplot of anti-CD14 reactivity vs. SSC orthogonal light-
scatter profile to allow the distinction of monocytes and
PMNs. Isotype-matched control samples confirmed spe-
cificity and served to define quadrant markers for two-
dimensional dot-plot and fluorescence histogram analy-
sis of positive and negative cell populations. Subsequent
data analysis was performed using FlowJo software v.8.7
(Tree Star Inc., Ashland, OR). Results are expressed as
the frequency of marker-positive events (% positive
cells) and as indirect measures of cell-surface antigen
density using linear mean fluorescence intensity (MFI).
Determination of Serum Cytokines and Soluble Adhesion
Molecule Concentrations
Blood samples collected into non-additive tubes were
a l l o w e dt oc l o ta tr o o mt e m p e r a t u r ea n dt h e nc e n t r i -
fuged at 1000 ×g for 15 min. The serum supernatants
were separated into 0.5-mL aliquots and frozen at -80°C
until batch analysis. Samples were subsequently thawed
immediately before analyses and assayed in duplicate for
circulating concentrations of TNF-a, IL-10, sICAM-1,
sVCAM-1, sE-selectin and sL-selectin, using commer-
cially available quantitative ELISA kits according to the
according to the manufacturer’s protocol (Quantikine®,
R&D systems Inc., Minneapolis MN). Absorbance was
read at 450 nm with wavelength correction in an auto-
mated microplate photometer (EL340, BIO-TEK Instru-
ments, Winooski, VT). Assay sensitivities for TNF-a
and IL-10, corresponded to 0.12 and 0.5 pg/mL, respec-
tively; sICAM-1, sVCAM-1, sE-selectin and sL-selectin
had detection limits 0.096, 0.6, 0.009 and 0.3 ng/mL,
respectively.
Statistical Analysis
Baseline demographic and clinical characteristics are
expressed as the mean ± standard deviation (SD). Data
were assessed for normality and homogeneity of var-
iance. Biomarker levels were treated as normally distrib-
uted continuous variables and expressed as mean ±
standard error of the mean (SEM). Univariate and mul-
tivariate techniques were used according to the type of
data being tested: intergroup comparisons between
dichotomous variables including demographic and clini-
cal characteristics were performed using Student’s t-test
for continuous variables and c
2 test for categorical pre-
dictor variables; and the non-parametric Mann-Whitney
U test for continuous variables that were not normally
distributed. Serial comparisons (time × treatment)o f
biomarkers between the treatment groups and control
group were made using repeated measures ANOVA
with post-hoc Bonferroni/Dunn testing. All analyses
were two-tailed, with a p-value < 0.05 indicating statisti-
cal significance.
Results
Patient Demographics and Clinical Characteristics
Table 1 summarizes demographic, injury and clinical
characteristics of TBI patients enrolled into the sub-
study. The two fluid-treatment arms were well balanced
with respect to age, GCS and other prognostic factors.
There were no significant differences in presenting
symptoms between the HSD and NS groups, with the
exception of serum sodium and osmolality values, which
were elevated in the HSD group.
Circulating Leukocyte Counts
Total and differential leukocyte counts are shown in
Table 2. Relative to normal control values both groups
of resuscitated TBI patients exhibited a significant post-
traumatic leukocytosis (up to 3-fold higher) upon hospi-
tal admission, which persisted throughout the 48-h
observation period. Differential analyses revealed the
Table 2 Absolute leukocyte counts and relative subset proportions in TBI patients and controls.
Parameter Control HSD NS
Adm (≤ 3 h) 12 h 24 h 48 h Adm (≤ 3h ) 1 2h 2 4h 4 8h
Leukocytes
Counts
1 5.7 ± 0.1 13.0 ± 0.1* † 11.3 ± 0.3* 11.4 ± 0.6* 10.4 ± 0.2* 18.1 ± 0.8* 12.3 ± 0.6* 11.5 ± 0.2* 11.4 ± 0.5*
PMNs
Counts 3.5 ± 0.1 10.8 ± 0.3* † 9.4 ± 0.1* 9.6 ± 0.2* 8.8 ± 0.1* 15.8 ± 0.4* 10.7 ± 0.2* 9.7 ± 0.1* 9.8 ± 0.1*
% 60.8 ± 0.6 82.4 ± 0.6* 83.5 ± 0.5* 83.5 ± 0.8* 83.9 ± 0.3* 86.5 ± 1.0* 86.3 ± 0.8* 84.1 ± 0.6* 85.4 ± 0.5*
Monocytes
Counts 0.29 ± 0.01 0.54 ± 0.02* † 0.59 ± 0.03* 0.52 ± 0.02* 0.50 ± 0.04* 0.74 ± 0.04* 0.63 ± 0.02* 0.57 ± 0.03* 0.61 ± 0.01*
% 5.03 ± 0.13 4.37 ± 0.14 5.06 ± 0.13 4.64 ± 0.11 5.02 ± 0.12 4.14 ± 0.11 4.30 ± 0.12 5.27 ± 0.13 5.32 ± 0.11
1Mean ± standard error mean (SEM) cell concentrations (×10
9/L).
*P < 0.05 vs age-matched healthy controls;
†P < 0.05 vs time-matched NS-treated patients by ANOVA
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found neutrophilia (increased proportion and number)
and a lesser monocytosis. Compared to patients treated
with NS, HSD resuscitated patients showed significantly
lower total white cell, PMN and monocyte counts on
hospital admission, although beyond this time-point
values were not significantly different between treatment
groups.
Cell-Surface Adhesion and Degranulation Markers
Figure 1(A-D) shows the post-resuscitation time course
of spontaneous CD62L and CD11b cell-surface adhe-
sion molecule expression on fresh peripheral blood
PMNs and monocytes, obtained from TBI patients and
healthy blood donors. A majority (90-100%) of PMNs
and monocytes from patients and controls were found
to constitutively express CD62L and CD11b, with no
significant temporal or intergroup differences in the
proportion of cells bearing these receptors.
Significantly higher surface density as quantified as
mean fluorescence intensity (MFI) of CD62L and
CD11b was found on both PMNs and monocytes from
NS-treated patients on admission in comparison with
HSD patients and controls. Expression of CD62L by
PMNs and monocytes were elevated in the NS group
across all sample times relative to control, whereas
HSD treatment significantly down-regulated CD62L
expression at all time points. CD11b expression on
PMNs and monocytes exhibited a biphasic response
pattern in the NS group, with an initial upregulation
observed on admission, followed by a second peak at
48-h post-resuscitation. By contrast, after HSD, CD11b
levels remained relatively constant over time at levels
approaching control values.
Figure 2(A-B) illustrates the temporal pattern of cell
surface CD66b and CD63 degranulation marker expres-
sion on PMNs. Following resuscitation, both patient
groups exhibited significant PMN degranulation, as
Figure 1 Cell-surface expression of L-selectin (CD62L) and b2-integrin (CD11b) adhesion molecules on fresh peripheral blood
monocytes (A-B) and polymorphonuclear neutrophils (PMNs; C-D) assessed by whole blood immunofluorescence flow cytometry.
Results were expressed as mean fluorescence intensity (MFI ± SEM; bars) in arbitrary units (a.u.) and the percentage of receptor-positive cells
(circles), which correlate with antibody cell surface density. Blood was sampled serially from severe TBI patients resuscitated with normal saline
(NS, n = 13) vs hypertonic saline-dextran (HSD, n = 10), upon hospital admission (Adm) and 12, 24, and 48-h post-resuscitation, and from healthy
controls (n = 25). *P < 0.05 vs age-matched healthy controls (n = 25);
†P < 0.05 vs time-matched NS-treated patients by ANOVA.
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the specific granule marker CD66b in comparison to
control. While the NS group showed progressively
increasing levels of CD66b over time, HSD-treated
patients displayed significantly lower CD66b protein
density at all time points, which normalized by 48-h.
Neither resuscitation strategy was found to influence
PMN expression of CD63-positive azurophilic granules,
since the surface density did not differ between patients
and healthy controls at any time-point.
Soluble Adhesion Molecules
Serum concentrations (ng/mL) of the panel of four solu-
ble adhesion molecules assayed in patients and healthy
controls are shown in Figure 3(A-D). These soluble
markers displayed unique kinetics of appearance in
serum with significant differences observed between
treatment groups. Concentrations of sVCAM-1 were
significantly elevated upon admission in the NS group
as compared to HSD-resuscitated patients and controls.
sVCAM-1 levels continued to rise in all patients over
time with peak values attained 48-h post-resuscitation in
HSD patients. Similarly, admission concentrations of
sICAM-1 were higher in the NS group as compared to
HSD and also reached a maximum at 48-h. Compara-
tively, sE-selectin time-course values were markedly ele-
v a t e di nt h eN Sg r o u pc o m p a r e dt oH S Da n dc o n t r o l
values. In contrast to the other measured soluble adhe-
sion molecules, sL-selectin concentrations were signifi-
cantly lower on admission in all patients in comparison
with healthy controls. In HSD-resuscitated patients sL-
selectin concentrations reached control values at 12 and
48 h, but levels remained depressed in the NS group
throughout the observation period.
Serum Cytokine Concentrations
As shown in Figure 4 (A-B), the serum concentrations (pg/
mL) of proinflammatory TNF-a and antiinflammatory IL-
10 in resuscitated TBI patients were both markedly higher
than those in control subjects. In particular, admission
levels of TNF-a were 10-fold greater in NS-treated patients
relative to control, and double those values observed in
HSD patients. By comparison, TNF-a concentrations in
HSD-treated patients did not show temporal variations but
remained moderately above control values throughout the
observation period. Peak serum IL-10 levels were 30-fold
higher in the NS group on admission relative to control,
and twice as high as HSD patients at all time points. IL-10
declined progressively over the observation period in both
groups but remained above normal at 48 h.
Plasma Coagulation Markers
At the time of hospital admission, measurements of
standard hemostasis indicators including INR, aPTT and
platelet counts were within their normal ranges in both
groups of TBI patients (Table 1); however, analyses of
plasma concentrations of TF, TM, and D-D revealed
pronounced differential effects of the two resuscitation
strategies on patient coagulation profiles (Fig. 5A-C.
Plasma concentrations of TF and D-D were significantly
elevated in NS compared to HSD and control values. By
contrast, HSD-resuscitated patients demonstrated signif-
icantly higher TM levels versus NS and control groups.
Stratification of Biomarker Levels According to
Dichotomized GOS
GOS scores at the time of hospital discharge/death within
30-days were dichotomized as Poor versus Good (i.e., GOS
score of 1-3 vs. GOS score of 4-5, respectively). After
dichotomization of the mean admission values for cellular
Figure 2 Cell-surface expression of specific (CD66b; A) and azurophilic (CD63; B) granular proteins on fresh polymorphonuclear
neutrophils (PMNs), assessed by whole blood immunofluorescence flow cytometry. Results were expressed as mean linear fluorescence
intensity (MFI ± SEM; bars) in arbitrary units (a.u.) and the percentage of receptor-positive cells (circles). Blood was sampled serially from severe
TBI patients resuscitated with normal saline (NS, n = 13) vs hypertonic saline-dextran (HSD, n = 10), upon hospital admission (Adm) and 12, 24,
and 48-h post-resuscitation, and from healthy controls (n = 25). *P < 0.05 vs age-matched healthy controls (n = 25);
†P < 0.05 vs time-matched
NS-treated patients by ANOVA.
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further stratified according to fluid resuscitation groups
(Table 3). Overall, the marker levels were significantly
higher in patients who had a poor outcome or died than
in those who survived with good outcome, irrespective of
fluid treatment. Further subgroup analysis revealed that
HSD-resuscitated patients showing a good neurological
outcome according to dichotomized GOS 4-5 scores
exhibited the lowest levels of cellular and soluble markers.
Conversely, the highest levels of most markers were
observed in NS-resuscitated patients with poor outcome
GOS 1-3. The notable exceptions to this pattern were sL-
selectin and TM, which showed the lowest levels in those
NS-treated patients with poor outcome.
Discussion
It is generally accepted that severe head injury causes a
profound inflammatory response within the brain
leading to breakdown of the BBB with peripheral leu-
kocyte invasion [5,48]. There is also abundant evidence
for reciprocal alterations between CNS and peripheral
inflammatory cells/mediators, which initiate systemic
inflammatory cascades [4,49,50]. Growing recognition
of the limitations of isotonic fluids for cerebral resusci-
tation has led to the search for alternative osmotic
agents aimed at restoring cerebral perfusion and redu-
cing intracranial pressure, while simultaneously confer-
ring neutroprotection. In this randomized controlled
trial, we investigated the potential immunomodulatory
effects of prehospital HSD resuscitation on the produc-
tion and interplay of leukocyte and endothelial adhe-
sion molecules, cytokines, and coagulation cofactors in
severe TBI patients. Although there is extensive precli-
nical and clinical experience evaluating the use of
hypertonic fluids for their superior volume-expanding
properties following extra-cranial insults, little is
known concerning the potential impact of
Figure 3 Serum concentrations (mean ± SEM, ng/mL) of soluble vascular cell adhesion molecule (sVCAM-1), intercellular adhesion
molecule (sICAM-1), endothelial selectin (sE-selectin) and leukocyte selectin (L-selectin) in severe TBI patients resuscitated with
normal saline (NS, n = 35) or hypertonic saline-dextran (HSD, n = 30) and healthy controls (n = 25). Blood was sampled serially upon
hospital admission (Adm) and 12, 24, and 48-h post-resuscitation. *P < 0.05 vs age-matched healthy controls (n = 25);
† P < 0.05 vs time-
matched NS-treated patients by ANOVA.
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Page 8 of 17hyperosmolar therapy on acute immunoinflammatory
response after isolated head injury [17,51]. HS/D has
been shown to dampen posttraumatic hyperinflamma-
tory responses and aberrant leukocyte-EC interactions,
leading to reduced tissue cytotoxicity and end-organ
damage in animal models of resuscitated hemorrhagic
shock [52]; and recently the beneficial immunoregula-
tory properties of HS/D have also begun to translate
into successful clinical trials of trauma patients [12,14].
However, to our knowledge, this is the first study to
investigate the effects of HSD on the activation of
cellular and molecular inflammatory/coagulation cas-
cades initiated by TBI.
Leukocyte and endothelial cell activation/adhesion
molecules
Posttraumatic leukocyte adherence and activation are
critical mediators of the pathogenesis of host tissue
injury. In this study, we assessed the role of specific leu-
kocyte and endothelial-derived activation/adhesion
molecules in resuscitated TBI patients. Our results pro-
vide evidence that the expression of cell-associated and
soluble adhesion molecules in severe TBI is differentially
Figure 4 Kinetics of serum concentrations (mean ± SEM, pg/mL) of pro- and anti-inflammatory cytokines TNF-a and IL-10 sampled
serially in normal saline (NS, n = 35) and hypertonic saline-dextran (HSD, n = 30) resuscitated TBI patients, upon hospital admission
(Adm), 12, 24, 48-h post-resuscitation.* P < 0.05 vs age-matched healthy controls (n = 25);
†P < 0.05 vs time-matched NS-treated patients by
ANOVA.
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After conventional crystalloid resuscitation, we found
that relative to healthy controls, brain-injured patients
exhibit extensive leukocyte mobilization, with signifi-
cantly enhanced PMN and monocyte surface expression
of L-selectin (CD62L) and b2-integrin (CD11b) adhesion
molecules, along with exocytosis of the specific granular
protein (CD66b). Along with increased expression of
membrane-bound adhesion molecules, our analysis
revealed that brain trauma caused elevated circulating
levels of sE-selectin (sCD62E), sICAM-1 (sCD54) and
sVCAM-1 (sCD106), but lower sL-selectin levels. A
Figure 5 Plasma concentrations of tissue factor (sTF; A), thrombomodulin (sTM; B) and D-dimers (D-D; C) in TBI patients resuscitated
with normal saline (NS, n = 30) or hypertonic saline-dextran (HSD, n = 25) at the time of hospital admission.* P < 0.05 vs age-matched
healthy controls (n = 25);
†P < 0.05 vs time-matched NS-treated patients by ANOVA.
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edly attenuated TBI-induced changes in these vital cell-
associated and soluble molecules compared to NS.
The prominent neutrophilia and monocytosis
observed in TBI patients is a well-known feature of
acute inflammation that is consistently reported in
patients sustaining polytrauma and closed head-injury
[53]. This reflects the sympathetic hormonal surge fol-
lowing severe tissue damage, which massively mobilizes
leukocytes into the circulation from the marginal pool
in the microvasculature. As observed in the current
study [14], we previously reported that early resuscita-
tion with HSD greatly reduces shock-associated leuko-
cyte redistribution via inhibition of catecholamine
release. The ability of HSD to attenuate the magnitude
of post-injury leukocytosis is clinically relevant since ele-
vated leukocyte counts on hospital admission reliably
correlate with adverse neurological outcome and mortal-
ity risk after TBI [54].
Leukocyte infiltration of the CNS is a hallmark of neu-
roinflammation and a key mechanism contributing to
the neuropathogenesis of secondary brain injury [25,29].
Cerebral edema, raised intracranial pressure and neuro-
toxicity are mediated, at least in part, by intracerebral
accumulation of blood-borne leukocytes [55,56]. Traf-
ficking of inflammatory cells from the bloodstream into
the brain parenchyma depends upon the regulated
expression of paired adhesion molecules on the surface
of infiltrating leukocytes and cerebrovascular ECs
[29,30]. Results of this study show that leukocytes from
TBI patients resuscitated with NS display rapid induc-
tion of constitutively expressed CD62L and activation of
CD11b with translocation to the cell membrane from
intracellular secretory granules [31]. Consistent with
these findings, studies in humans and animals demon-
strate upregulated cell-surface CD62L and CD11b
expression on leukocytes following polytrauma and iso-
lated head-injury [57]. CD11b expression is also closely
associated with CD66b (co-localized in specific granules)
and upon ligation forms a macromolecular complex that
induces clustering of b2-integrins molecules, which
potentiates avid binding to the endothelium with release
of inflammatory mediators [58]. Importantly, the current
results, showing that HSD prevents TBI-induced upre-
gulation of leukocyte adhesion molecules, confirm pre-
vious in vitro human cellular studies [59,60], animal
models [13,61,62] and clinical trials [12,14] of shock/
resuscitation, demonstrating that hypertonicity inhibits
leukocyte adherence and activation via downregulation
of selectins, integrins and immunoglobulin molecules,
thus rendering cells incapable of rolling or adhering to
the endothelium.
Experimental studies show widespread microvascular
endothelial activation [20,63] with upregulated adhesion
molecule expression within 2-4 hours of neurological
injury [24,64]. E-selectin is not normally present on
non-inflamed cerebrovascular ECs, but is dramatically
induced at the transcriptional level by inflammatory sti-
muli and upregulated expression mediates initial adher-
ence of PMNs and monocytes to brain microvasculature
after traumatic/ischemic insults [65]. Likewise, the con-
stitutively low expression of ICAM-1 and VCAM-1 is
rapidly upregulated on the cytokine-activated cerebro-
vascular ECs facilitating adhesion and transmigration of
leukocytes into the CNS [35,66,67]. Immunohistochem-
ical staining and microscopic analyses reveal early
Table 3 Admission levels of inflammatory and coagulation biomarkers in patients according to dichotomized Glasgow
Outcome Scores (GOS) and resuscitation treatment group.
Marker GOS Score
HSD NS
Poor (1-3) Good (4-5) Poor (1-3) Good (4-5)
CD62L, MFI
§ 48.5 ± 4.6
b 33.7 ± 4.7
a,b 58.5 ± 5.9 45.3 ± 4.4
a
CD11b, MFI
§ 443.3 ± 58.7
b 377.4 ± 28.3
a,b 539.3 ± 91.8 505.9 ± 51.4
CD66b, MFI
§ 124.4 ± 28.4 74.6 ± 7.2
a,b 135.1 ± 17.9 118.0 ± 8.3
a
sICAM-1, pg/mL 228.3 ± 28.3
b 211.1 ± 19.1
b 254.4 ± 13.5 238.4 ± 29.0
sVCAM-1, pg/mL 713.8 ± 67.3
b 574.2 ± 70.0
a,b 757.0 ± 60.3 741.1 ± 54.8
sE-Selectin, pg/mL 33.9 ± 3.0
b 31.1 ± 4.0
b 45.2 ± 3.8 42.5 ± 4.6
sL-Selectin, pg/mL 849.2 ± 64.7
b 875.2 ± 87.3
b 770.3 ± 69.4 870.1 ± 60.0
a
TNF-a, pg/mL 7.2 ± 2.4
b 4.9 ± 1.7
a,b 14.8 ± 1.4 6.9 ± 1.3
a
IL-10, pg/mL 19.6 ± 6.3
b 12.9 ± 2.2
a,b 30.3 ± 4.9 26.4 ± 4.8
a
TF, pg/mL 42.0 ± 4.3
b 39.5 ± 12.6
b 78.7 ± 10.5 65.8 ± 15.9
a
TM, ng/mL 4.0 ± 1.1
b 3.6 ± 1.3
b 2.1 ± 1.3 2.8 ± 1.1
D-D, μg/mL 6.8 ± 2.3
b 6.4 ± 1.2
b 12.1 ± 2.1 7.6 ± 1.9
a
Data are expressed as mean ± standard error mean (SEM) for each marker.
§ MFI, mean fluorescence intensity of surface antigen expression by neutrophils.
Abbreviations: NS, normal saline; HSD, hypertonic saline-dextran; GOS, Glasgow Outcome Scale score.
aP < 0.05 vs GOS 1-3;
bP < 0.05 vs NS treated patients, by unpaired t-test.
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peaks approximately 24 h after severe neurotrauma [68]
and progresses to a predominance of monocyte/macro-
phage infiltrate by 72 h post-injury [69]. The temporal
profile of cell recruitment in these earlier reports is con-
sistent with the peak kinetics of CD62L and CD11b
molecule expression we observed on blood PMNs and
monocytes. Inappropriate sequestration of adherent leu-
kocytes in postcapillary venules may aggravate neurovas-
cular damage by further impairing cerebral blood flow
[41] and by intracerebral release neurotoxic mediators
[34].
The damaging role of infiltrating leukocytes in cere-
bral injury is substantiated by studies in which PMN
depletion or administration of anti-adhesion antibodies
[70] reversed impaired tissue perfusion, BBB dysfunction
and reduced infarct size [30]. Furthermore, the extent of
PMN accumulation is correlated with the degree of cer-
ebral edema, injury severity, and poor outcome follow-
ing TBI [21,55]. Although direct examination of cerebral
leukocyte invasion was not possible in the present study,
our recent findings in the same cohort of TBI patients
showing marked elevations of serum S100B and NSE as
indicators of brain damage after resuscitation with NS
[44], are strongly suggestive of neuroinflammation, BBB
impairment and cellular infiltration that may be amelio-
rated by HSD [45,46]. This assertion is also supported
by intravital microscopy studies showing inhibition of
leukocyte-EC interactions by hypertonic saline reduces
microvascular permeability and tissue injury [13], and
prevents BBB disruption allowing less intracerebral leu-
kocyte sequestration in brain-injured animals compared
to Ringers’s [51,71].
Many adhesion molecules exist as both transmem-
brane proteins and biologically active soluble forms aris-
ing from proteolytic cleavage of the extracellular region
of the membrane-bound molecule [42]. Increased levels
of soluble adhesion molecules are reported in a variety
of inflammatory conditions [72]. Although their physio-
logical role(s) and clinical relevance is not fully resolved,
it is generally accepted that elevated concentrations of
these endothelial derivatives are liberated by activation-
induced shedding, or arise as a result of direct vascular
damage [73]. Our results showing enhanced serum con-
centrations of sE-selectin, sICAM-1 and sVCAM-1 are
in accordance with the pattern of release of soluble
selectins and immunoglobulin-type adhesion molecules
characterized several experimental and clinical studies
following brain injury [24,74,75]. High circulating con-
centrations of these molecules may serve as biomarkers
for early diagnosis or prognosis of the development of
the systemic inflammatory response syndrome, organ
dysfunction and death after severe trauma or sepsis [76].
Similarly, increased sICAM-1 levels are reported to
correlate with the extent of brain damage and break-
down of the BBB leading to poor outcomes after TBI
[77]. Correspondingly, we found the highest levels of sE-
selectin, sICAM and sVCAM in association with poor
neurological outcome (i.e., GOS 1-3) in NS resuscitated
patients. Notably, the only published study assessing the
effects of hypertonic saline on the circulating profile of
soluble adhesion molecules found lower sICAM-1 levels
in the CSF of severe trauma patients compared to lac-
tated Ringer’s [78].
Soluble adhesion molecules are suggested to serve a
functional role, either by inhibiting ongoing immunoin-
flammatory responses by competitive binding or conver-
sely by inducing a response in ligand-bearing cells [72].
For instance, elevated sE-selectin and sICAM-1 have
been shown to activate leukocytes following neurological
insult [24], whereas high sL-selectin levels are closely
associated with decreased cellular interactions and
reduced microvascular damage in critically injured
patients [79]. Our findings of initially low sL-selectin
levels in TBI patients are consistent with earlier studies
showing an inverse relationship between sL-selectin
concentrations and increased risk of organ failure or
death following isolated head injuries [80]. Furthermore,
the current results showing reduced surface expression
of CD62L in HSD-treated patients, accompanied by cor-
responding increases in sL-selectin and better patient
outcome, are in accordance with our previous findings
in shock patients [14], and supports the theory that sL-
selectin shedding represents an endogenous regulatory
mechanism to limit leukocyte-mediated injury [79].
Inflammatory Cytokines
Cytokines are critical mediators of neuroinflammation
after TBI [5,23], regulating a wide-variety of cellular
functions through autocrine and paracrine signaling net-
works that initiate and perpetuate inflammatory reac-
tions [25]. Severe TBI is associated with rapid and
substantial increases in the synthesis and release of var-
ious pro/antiinflammatory cytokines into CSF and blood
[4]. Experimental models of closed-head injury [30] and
clinical studies [81,82] of TBI demonstrate early induc-
tion of TNF-a and IL-1b that peaks within 3-8 h of
injury, followed by more sustained elevations of IL-6
and IL-10 [5,83]. In this study, we focused on the proto-
typical pro- and antiinflammatory cytokines, TNF-a and
IL-10, respectively, since large increases in both corre-
late with head injury severity and are indicative of poor
clinical outcome [84]. Like earlier experimental and clin-
ical studies, our findings indicate peak serum concentra-
tions of TNF-a and IL-10 are detectable within the first
3 h of injury, but remain above control values for up to
48 h. These cytokines are produced systemically and in
high concentrations by resident microglia and infiltrat-
ing monocyte/macrophages in the acute phase of injury
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tion [28], causing enhanced BBB permeability [29] and
upregulated expression of adhesion molecules such as
ICAM-1 and VCAM-1 on the surface of brain ECs and
glial cells [24,85], exacerbating intracerebral leukocyte
infiltration and microcirculatory dysfunction [23,41].
Inflammatory cytokines also stimulate astrocyte reactiv-
ity, contributing to increased neuroinflammation and
development of secondary injury following neurotrauma
[22,86]. Correspondingly, recent in vivo and in vitro ani-
mal studies have shown that both central and peripheral
osmotic stimulation with hypertonic saline attenuates
the brain’s innate immune response to injury, reducing
microglial activation, astrocytosis, cytokine production
and associated neural tissue loss [15,16].
Ar e m a r k a b l ef i n d i n go ft h ec u r r e n ts t u d yw a st h a t
HSD resuscitation halved the multifold increases in
both TNF-a and IL-10 observed upon admission, but
levels remained elevated for at least 48-h in compari-
son to control values. Although, this is the first pub-
lished report of the effects of HSD on cytokine
production after TBI, our results are consistent with
several earlier studies in humans and animals demon-
strating a more balanced pro versus antiinflammatory
cytokine profile following hypertonic resuscitation of
hemorrhagic shock or sepsis[ 5 2 ] .P r e v i o u ss t u d i e s
examining TNF-a gene transcription and protein
expression in response to hypertonicity have consis-
tently shown inhibition in animal models of posttrau-
matic shock/resuscitation [87,88], in vitro exposure of
human peripheral blood cells to hypertonic media
[89-91], and ex vivo intracellular production by blood
monocytes of resuscitated trauma patients [14].
Reports of endogenous IL-10 responses to hypertoni-
city are less consistent, exhibiting differential expres-
sion according to the dose administered, timing of
treatment, type of injury, and tissue sample specificity.
For example, we have demonstrated previously that in-
hospital resuscitation with HSD enhances spontaneous
and LPS-stimulated IL-10 expression in blood mono-
cytes of shock patients [14], which corresponds with
increased production by tissue macrophages in rodent
models of shock/resuscitation [92-94]. By contrast, our
present findings show that pre-hospital HSD treatment
of TBI induced a roughly 50% reduction in circulating
IL-10 levels lasting for at least 24 h, compared to NS.
Similarly, clinically relevant doses of hypertonic saline
in vitro were found to suppress IL-10 production in
isolated LPS-stimulated human gδT cells [91] and to
decrease circulating IL-10 concentrations in rats sus-
taining shock/resuscitation [9].
The ability of HSD to attenuate, but not abrogate,
cytokine responses after TBI may be critical in light of
their proposed duality in mediating both protective and
injurious roles [27]. It has been suggested that high
levels of TNF-a exert deleterious effects on the progres-
sion of tissue damage during the acute stages of CNS
i n j u r y ,b u tp l a yar e p a r a t i v er o l ea tl o w e rl e v e l s[ 2 ] .
Also, the relatively low IL-10 concentrations seen in
HSD patients are consistent with the premise that mod-
erate sustained levels of this potent antiinflammatory/
immunosuppressive cytokine may be neuroprotective in
early pathogenesis and subsequent termination of neu-
roinflammation, but detrimental at high levels [84,95].
In fact, it has been reported that up to 50% of isolated
head-injury patients who survive an initial neurological
insult subsequently die as a result of infection or non-
neurological organ dysfunction [4]. Paralysis of cell-
mediated immunity following severe TBI, partially
induced by enhanced sympathetic-mediated IL-10
release, appears to be responsible for systemic immuno-
suppression with increased susceptibility to infectious
complications [96]. This is consistent with our data
showing that NS treated patients with poor outcome
according to GOS score also exhibit the highest levels of
TNF-a and IL-10. These findings support the idea that
HSD leads to a more homeostatic cytokine profile that
may alter secondary injury processes without compro-
mising neurologic recovery.
Coagulation Molecules
T h ep o s t t r a u m a t i ci n f l a m m a t o r yr e s p o n s ei m p i n g e s
upon hemostatic regulatory mechanisms at multiple
levels, including effects on procoagulant, anticoagulant
and fibrinolytic systems [43]. Patients sustaining severe
injury are at risk for coagulopathy due to concurrent
hypothermia, blood loss, acidosis, and hemodilution
[97]. Coagulation disorders are a frequent complication
in patients with head injuries [26], which can be either
hypercoagulable or hyperfibrinolytic and represent a
powerful, independent predictor of prognosis [98]. TBI-
associated hypercoagulability is associated with injury-
mediated disruption of the cerebrovasculature with
exposure of abundant subendothelial TF to circulating
factor VII initiating the extrinsic pathway [18]. Intrave-
nous fluids contribute to dilutional coagulopathy and
also show intrinsic effects on the hemostatic system
[99], but relatively few studies refer to the functional
consequences after hypertonic resuscitation [100] and
none evaluating the effects of HS/D on coagulation in
TBI patients. Available in vitro and in vivo laboratory
data suggest that hypertonic fluids exerts dose-depen-
dent anticoagulant activity in animals or in serially
diluted normal human plasma, as determined by routine
clot-based assays and thromboelastography [101-104].
These studies provide evidence of direct anticoagulant
effects of hypertonicity on plasma clotting factors and
platelet activity and/or through interaction with inflam-
matory pathways [104,105].
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pathy, as defined by standard clinical tests (i.e., INR >
1.3 or aPTT > 34 s), but significant differences were evi-
dent in circulating concentrations of coagulation cofac-
tors between treatment groups. Based on the measured
plasma sTF, sTM and D-D levels, our results show that
compared to control, NS-resuscitated TBI patients exhi-
bit activation of coagulation with concurrent down-reg-
ulation of anticoagulant systems and fibrinolysis.
Furthermore, a key finding of this study was that HSD
reduced TBI-induced increases in sTF and D-D levels
by half, while maintaining sTM levels near control
values. This suggests that hypertonic resuscitation may
act to improve coagulofibrinolytic balance after TBI.
Previous studies have shown liberation of a soluble TF
from both vascular and extravascular sources following
traumatic injury [36]. sTF is released into the circulation
within hours of head injury [106], and inducible TF
expression is rapidly upregulated on the surface of cir-
culating monocytes after injury [38]. Although the
source of the early increase in sTF is not clear, it likely
the result of cleavage from TF-bearing monocytes and/
or release from dysfunctional brain ECs in response to
inflammatory cytokines [18,39]. Elevated systemic and
intracerebral TNF-a release after TBI has been shown
to have procoagulant effects, stimulating synthesis and
release of sTF while suppressing cell-surface TM levels
and the protein C pathway [35]. Normally, TM acts to
control hemostasis through high-affinity binding of
thrombin, which activates anticoagulant and antiinflam-
matory protein C pathways [40,97]. Elevated levels of
sTM, as in the current study, are thought to reflect
increased surface expression and shedding of transmem-
brane TM, which plays a role in regulating not only
hemostasis, but also inflammation, thus providing a
close link between these processes [40]. Although the
biological relevance of changes in sTM in brain injury is
not well characterized [35], emerging data from clinical
and animal studies suggest that increases in endogenous
sTM or exogenous administration of TM may have
potent antithrombotic/antiinflammatory properties in
inflammatory disease [107].
In conclusion, this study of severe head injury patients
demonstrates that prehospital treatment with HSD
attenuates inflammatory and coagulation cascades by
modulating leukocyte and endothelial cell adhesion/acti-
vation molecule expression, pro/antiinflammatory cyto-
kine release and pro/anticoagulant responses. These
findings provide direct evidence that initial resuscitation
with HSD imparts functional changes to inflammatory
cells after TBI, which may inhibit the capacity for infil-
tration of damaged CNS tissues, thereby reducing
potential neuroinflammatory events associated with sec-
ondary brain injury. Our results also suggest that by
downregulating inflammatory mediator production,
HSD may help prevent procoagulant TF-dependent
derangements of hemostasis and fibrinolysis, which may
otherwise contribute to intravascular thrombosis.
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